# Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

> **NCT03558997** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Timothy Grass SCIT
- **DRUG:** Placebo matching dupilumab
- **DRUG:** Placebo matching SCIT

## Key facts

- **NCT ID:** NCT03558997
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-06-13
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03558997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03558997, "Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03558997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*